Curriculum Vitae

EDUCATION:

Undergraduate Education:
STANFORD UNIVERSITY, Stanford, California. B.S., 1976. Interdepartmental major in biophysics

MEDICAL EDUCATION:

BAYLOR COLLEGE OF MEDICINE, Houston, Texas, M.D., 1980

POST-GRADUATE TRAINING:

  • Internship, Wadsworth Veterans Administration Medical Center (Medicine/Neurology) and UCLA Neuropsychiatric Institute (Geroneuropsychiatry/Neurology). July 1980-June 1981.
  • Psychiatry Resident, UCLA Neuropsychiatric Institute. July 1981-July 1984.
  • Robert Wood Johnson Clinical Scholar, UCLA Clinical Scholars Program. July 1984-June 1986.

LICENSURE: MEDICAL BOARD OF CALIFORNIA, Certificate No. A37496

BOARD CERTIFICATION:

  • Diplomate, Added Qualification in Geriatric Psychiatry, American Board of Psychiatry and Neurology, 1991 and 2001
  • Diplomate, American Board of Electroencephalography and Neurophysiology, 1990
  • Diplomate in Psychiatry, American Board of Psychiatry and Neurology, 1986

ACADEMIC APPOINTMENTS:

  • Professor, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA. July 2000 – present
  • Director, Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior at UCLA. June 2015 – present
  • Director, Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA. September 2002 – present
  • Chair, UCLA Academic Senate. September 2011 – August 2012
  • Vice Chair/Chair-Elect, UCLA Academic Senate. September 2010 – August 2011
  • Associate Dean, David Geffen School of Medicine at UCLA. July 2008 – June 2009
  • Responsible Executive Officer, UCLA Donated Body Program. July 2008 – June 2009
  • Daniel X. Freedman Professor, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA. July 2003 – June 2006
  • Vice Chair, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA. September 2002 – June 2006
  • Professor-in-Residence, Department of Psychiatry and Biobehavioral Sciences, UCLA Neuropsychiatric Institute, July 1999 – June 2000
  • Senior Research Scientist, Semel Institute for Neuroscience and Human Behavior at UCLA. September 2000 – present
  • Director, Division of Adult Psychiatry, UCLA Department of Psychiatry and Biobehavioral Sciences, and UCLA Neuropsychiatric Institute and Hospital, January 1998 – June 2003
  • Chief of Staff, UCLA Neuropsychiatric Hospital. July 2001 – June 2003
  • Vice Chief of Staff, UCLA Neuropsychiatric Hospital. July 1999 – June 2001
  • Director, Office of Professional and Community Education, Semel Institute for Neuroscience and Human Behavior at UCLA. September 1995 – present
  • Director, Quantitative Electroencephalography Laboratory, UCLA Neuropsychiatric Institute and Hospital. January 1986 – present
  • Member, UCLA Brain Research Institute, July 1991 – present
  • Associate Professor-in-Residence, Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine. July 1994 – July 1999
  • Assistant Professor-in-Residence, Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine. July 1986 – July 1994
  • Director, Clinical Core, UCLA Alzheimer’s Disease Center. September 1991 – 2000
  • Associate Director, Geriatric Services, UCLA Neuropsychiatric Hospital. March 1995 – December 1997
  • Co-Director, Geropsychiatry Inpatient Service, UCLA Neuropsychiatric Institute and Hospital. July 1986 – July 1992
  • Staff Psychiatrist, Medication Development Unit, West Los Angeles VA Medical Center. July 1992 – June 1999

PROFESSIONAL ACTIVITES: 

Membership in Professional Societies:

  • American Psychiatric Association
  • Southern California Psychiatric Association
  • American Association for Geriatric Psychiatry
  • EEG and Clinical Neuroscience Society

Service to Organizations:

  • Council Member-at-Large, American Medical EEG Association. 1990-1995
  • Member, Medical and Scientific Advisory Board, Alzheimer’s Association. California Southland Chapter, 1991-present
  • Chair, Physician Education Subcommittee, Alzheimer’s Association, California Southland Chapter, 1992-1996
  • Member, Education Committee, Alzheimer’s Association, California Southland Chapter, 1992-1999
  • Chair, Los Angeles Area Alzheimer’s Disease Biennial Conference, 1995
  • Member, Executive Committee, Sequenced Treatment Alternatives to Relieve Depression (STAR*D), December 2002 – December 2004

Editorial Service to Scholarly Publications:

  • Assistant Editor, American Journal of Geriatric Psychiatry, 1993 – 2000
  • Reviewer for JAMA Psychiatry, American Journal of Geriatric Psychiatry, American Journal of Psychiatry, Journal of the American Psychiatric Association, BMC Psychiatry, JAMA, Journal of the American Geriatric Society, International Journal of Geriatric Psychiatry, International Journal of Clinical Practice, Journal of Nervous and Mental Disease, Journal of Neuropsychiatry and Clinical Neurosciences, Alzheimer’s Disease: International Journal, Psychiatry Research, Biological Psychiatry, Journal of Clinical Psychiatry, Brain, Psychological Medicine, and European Neuropsychopharmacology.

UNIVERSITY SERVICE:

Academic Senate Committees: 

  • Member, Rebenching Budget Committee, UC Office of the President, September 2011 – June 2012
  • Chair, Council of Faculty Chairs/ Council of Senate Committee Chairs, September 2011 – June 2012
  • Vice Chair, Council of Faculty Chairs/ Senate Committee Chairs, September 2010 – August 2011
  • Member, Executive Board, September 2005 – August 2012
  • Member, Council on Planning and Budget, September 2007 – August 2010
  • Chair, IRB Operations Oversight Committee, September 2007 – 2011
  • Chair, Faculty Executive Committee, David Geffen School of Medicine at UCLA, September 2005 – September 2007
  • Vice Chair and Chair-Elect, Faculty Executive Committee, David Geffen School of Medicine at UCLA, September 2004 – August 2005
  • Member, Faculty Executive Committee, David Geffen School of Medicine at UCLA, August 2003 – September 2007

Campus-wide Committees and Task Forces:

  • Member, Information Technology Planning Board, September 2010 – 2011
  • Chair, RAPID Faculty Advisory Committee, Office of the Executive Vice Chancellor, December 2009 – present
  • Member, Executive Vice Chancellor’s Research Administration Organizational Assessment Steering Committee, September 2008 – present
  • Member, webIRB Executive Committee, Office of the Vice Chancellor for Research, September 2008 – 2011
  • Chair, Ad Hoc Task Force on Faculty Consulting, Office of Intellectual Property Administration and Industry Relations, September 2007 – June 2008
  • Chair, UCLA Conflict of Interest Review Committee, Office of the Vice Chancellor for Research, July 2006 – June 2009
  • Member, Conflict of Interest Review Committee (formerly known as the Independent Substantive Review Committee, UCLA), Office of the Vice Chancellor for Research, July 2005 – June 2009
  • Member, Chancellor’s Task Force on Clinical Research Process Improvement, January – July 2004

School of Medicine Committees:

  • Chair, Anatomical Materials Review Committee, July 2008 – June 2009
  • Chair, Committee on Industry Relations, October 2007 – June 2009
  • Member, Clinical Research Quality Assurance Committee, April 2007 – June 2009
  • Chair, Task Force on Prevention of Student Harassment, December 2003 – August 2004

Semel Institute for Neuroscience and Human Behavior, Neuropsychiatric Hospital, and Department of Psychiatry and Biobehavioral Sciences Committees:

  • Appointments and Advancements Committee, UCLA Department of Psychiatry and Biobehavioral Sciences, 1987-1992, 1995-1999
  • Utilization Review Committee, NPH, 1988
  • ECT Review Committee, NPH, 1988 – 1997
  • Mental Health Group Board of Directors, Department of Psychiatry and Biobehavioral Sciences, 1988 – 1990
  • Medical Records Committee, NPH, 1992 – 1997
  • Chair, ECT Review Committee, NPH, 1994 – 1997
  • Chair, Continuing Education Committee, Semel Institute for Neuroscience and Human Behavior, 1995 – present
  • Neuropsychiatric Behavioral Health Services Board of Directors, Department of Psychiatry and Biobehavioral Sciences, 1998 – 2003
  • Steering Committee, Department of Psychiatry and Biobehavioral Sciences, 1998 –2006
  • Director’s Forum, NPI, 1998 – 2006
  • Chair, NPI Residency Oversight Council, January 2003 – June 2006.
  • Chair, Faculty Advisory Board, Friends of the Semel Institute, September 2003 – present
  • Various Ad Hoc Review Committees, Council on Academic Personnel, 2002 – present
  • Various Ad Hoc Department Advancement Committees, 2002 – present
  • Member, Integrated Mood Disorders Committee, August 2009 – present

CONSULTING ACTIVITIES:

  • Consultant, Eli Lilly and Company, Indianapolis, IN 2001 – 2008
  • Chair, Data Safety and Monitoring Board for study H9P-MC-LNBI, Lilly Research Laboratories, Indianapolis, IN 2009 – 2010
  • Chair, Neuroscience Advisory Board, Aspect Medical Systems, Inc., Newton, MA 2002 – 2008
  • Consultant, Seaside Therapeutix, Cambridge, MA 2011 – 2012
  • Consultant, MedGenesis Therapeutix Inc., Oakland, CA 2012
  • Consultant, Genentech, Inc., San Francisco, CA 2013
  • Consultant, Neosync, Inc., Newton, MA and Newport Beach, CA 2010 – present
  • Consultant, CHDI Foundation, Inc., New York, NY 2009 – present
  • Consultant, Taisho Pharmaceuticals R&D Inc., Morristown, NJ 2013 – 2015

HONORS, AWARDS, AND RECOGNITIONS:

  • Award for Outstanding Research, June 1996, UCLA Research Conference on Aging. “NGF in Rats with Nucleus Basalis Lesions: Cholinergic and Quantitative Electroencephalographic Correlates,” Holschneider DP, Leuchter AF, Walton NY, Scremin OU, Treiman DM
  • Outstanding Research Mentor Award, UCLA Department of Psychiatry & Biobehavioral Sciences, 1996
  • Early Career Research Award, American Psychiatric Electrophysiology Association, 1997
  • Fellow, American Psychiatric Association, 2000
  • Member, Mental Disorders of Aging Review Committee, National Institute of Mental Health, 1998 – 2000
  • Ad hoc grant reviewer, National Center for Complementary and Alternative Medicine, National Institutes of Health, 2003 – 2008
  • Grant reviewer, Conte Center Study Section, National Institutes of Mental Health, 2009 – 2010
  • Invited presenter, “Brain Mechanisms in the Placebo Response,” Workshop sponsored by the National Institute of Mental Health and the Mind, Brain, Body, and Health Initiative. September 27 – 28, 2004
  • Invited presenter, “Using Biomarkers to Change the Way We Treat Depression,” Harold Visotsky, M.D. Memorial Lecture at Northwestern University Grand Rounds. April 25, 2007
  • Invited presenter, “Evidence-based Approaches to Neurophysiologic Testing in Depression,” 20thAnniversary Conference of the International Society for Neuroimaging in Psychiatry (ISNIP), September 13, 2008, Frankfurt, Germany
  • Invited presenter, North American Research Conference on Complementary and Integrative Medicine, National Center for Complementary and Alternative Medicine, Wednesday, May 13, 2009, Washington, DC
  • Invited presenter, University of Wisconsin School of Medicine and Public Health Psychiatric Update, October 23, 2009, Madison, WI
  • Invited presenter, 5th Annual HD Therapeutics Conference, CHDI, Inc., February 9, 2010, Palm Springs, CA
  • Invited presenter, XXVII CINP World Congress, CINP (International College of Neuropsychopharmacology), June 6-7, 2010, Hong Kong, SAR

RESEARCH SUPPORT:

Public Health Service Biomedical Research Support Grant RR5756. “Psychiatric Diagnosis of Dementia.” Andrew Leuchter, M.D., Principal Investigator. November 1, 1984 – June 30, 1986. $4,870.

“Mental Illness in the Elderly: Diagnostic Testing.” 1ROl MH/NS 40705-01. Andrew Leuchter, M.D., Principal Investigator. March 1, 1986 – February 28, 1989. $151,000.

Geriatric Mental Health Academic Award. 1KO7 MH00665-01. Andrew Leuchter, M.D.,

Principal Investigator. August 1, 1986 – July 30, 1989. $161,216.

“Early Detection of HIV Dementia.” American Foundation for AIDS Research. Andrew 

Leuchter, M.D., Principal Investigator. June 1, 1988 – May 30, 1989. $60,000.

“Mental Illness in the Elderly: Diagnostic Testing.” 1RO1 MH/NS 40705-04. Andrew Leuchter, M.D., Principal Investigator. August 1, 1989 – July 31, 1995. $1,372,055.

“Research Fellowship.” R-S901019. Support for Ian Cook, M.D., for The John E. Fetzer Institute, Inc. Andrew Leuchter, M.D., Principal Investigator. October 1, 1990 – September 30, 1991. $15,000.

“Alzheimer’s Disease Center.” AG10123-01. Jeffrey Cummings, M.D., Principal Investigator. Andrew Leuchter, M.D., Principal Investigator, Clinical Core. September 1, 1991 – August 30, 1996. $3,520,416.

“EEG Methods for the Assessment of Cerebral Function and Dysfunction.” Investigator-initiated Collaborative Research Agreement (W920415) with Neurodata, Inc. Andrew Leuchter, M.D., Principal Investigator. September 15, 1992 – September 14, 1993. $104,000.

“The Examination of Memory Processes in Elderly Adults Utilizing Quantitative Electroencephalography (qEEG)”. Fellowship for Ruth O’Hara, Ph.D., from The Brookdale Foundation. Andrew Leuchter, M.D., Principal Investigator. May 1, 1993 – April 30, 1995. $105,000.

“Research Fellowship.” Support for Daniel Holschneider, M.D., from American Geriatric

Society and Pfizer Inc. U.S. Pharmaceuticals Group. Andrew Leuchter, M.D., Principal Investigator. July 1, 1994 – June 30, 1996. $80,000.

“Neurophysiologic Monitoring of Antidepressant Treatment.” Investigator-initiated research grant from Lilly Research Laboratories. Andrew Leuchter, M.D., Principal Investigator. January 1, 1995 – April 30, 1996. $74,250.

Research Science Development Award. “Psychiatric Assessment of Cognition in the

Elderly.” 1 K02 MH01165-01. Andrew Leuchter, M.D., Principal Investigator. December 1, 1994 – November 30, 1999. $494,100.

“Mental Illness in the Elderly: Diagnostic Testing.” 1 R01 MH40705-09A2. Andrew Leuchter, M.D., Principal Investigator. September 30, 1995 – June 30, 2000. $1,969,032.

“Physiological Monitoring of Antidepressant Treatment Response.” Investigator-initiated research grant from Wyeth-Ayerst Laboratories. Andrew Leuchter, M.D., Principal Investigator. June 1, 1996 – December 31, 1997. $80,000.

“Alzheimer’s Disease Center.” P30 AG10123-06. Jeffrey Cummings, M.D., Principal

Investigator. Andrew Leuchter, M.D., Principal Investigator, Clinical Core. July 1, 1996 – June 30, 2001. $1,473,089.

“Research Training. Psychobiological Sciences.” T32 MH17140. Andrew Leuchter, M.D., Principal Investigator. July 1, 1998 – June 30, 2003. $1,065,720.

“Therapeutic Response to Reboxetine in Major Depression: Relationship to Pretreatment Cordance.” Investigator-initiated research grant from Pharmacia & Upjohn. Andrew Leuchter, M.D., Principal Investigator. November 1999 – April 2002. $282,346.

“Open Label Reboxetine Continuation Therapy.” Investigator-initiated research grant from Pharmacia & Upjohn. Andrew Leuchter, M.D., Principal Investigator. January 1999 – February 2002. $99,323.

Research Science Development Award. “Enhancing Treatment Outcomes in Depression.”

1 K02 MH01165-06. Andrew Leuchter, M.D., Principal Investigator. December 1999 – November 2004. $670,950.

“Physiologic Monitoring of Antidepressant Medication Effects in Normal Control Subjects.” Investigator-initiated research grant from Lilly Research Laboratories. Andrew Leuchter, M.D., Principal Investigator. December 1, 2000 – November 30, 2003. $122,880.

“Sequenced Treatment Alternatives to Relieve Depression” Subcontract from University of Texas Southwestern/NIMH. Andrew Leuchter, M.D., Regional Center Director. April 1, 2001 – September 30, 2004. $466,054.

“A Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Efficacy of MK-0869 in the Maintenance of Antidepressant Effect in Geriatric Outpatients with Major Depressive Disorder.” Research contract from Merck & Company. Andrew Leuchter, M.D., Principal Investigator. May 2002 – February 2004. $295,100.

“Open-Label Treatment w/Duloxetine HCl Once-Daily Dosing for Evaluation of Stabilization Dose in Patients with Major Depression.” Research contract from Eli Lilly & Company. Andrew Leuchter, M.D., Principal Investigator. December 2002 – December 03, 2005. $141,417.

“Research Training. Psychobiological Sciences.” T32 MH17140. Andrew Leuchter, M.D., Principal Investigator. July 1, 2003 – June 30, 2008. $1,414,704.

“Placebo Responder Evaluation using Comprehensive Investigation of Symptoms

and EEG (PRECISE).” Investigator-initiated research grant from Pfizer Global Medical Research (Biomarkers Development) and Lilly Research Laboratories. Andrew Leuchter, M.D., Principal Investigator. December 23, 2003 – June 30, 2006. $570,052.

“Psychobiologic Factors of the Placebo Response in MDD”. 1 RO1 AT002479-01. Andrew Leuchter, M.D., Principal Investigator. September 29, 2004 – June 30, 2009 (NCTE). $1,343,025.

“Depression Treatment Network.” Subcontract from University of Texas Southwestern/NIMH. Andrew Leuchter, M.D., Regional Center Director. September 29, 2004 – September 28, 2009. $162,887.

“Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome” Industry-initiated research grant from Eli Lilly and Company. Andrew F. Leuchter, M.D., Principal Investigator. October 01, 2005 – April 12, 2007. $174,435.

“Examination of Quantitative Electroencephalographic Biomarkers in Huntington’s Disease: A Pilot Project” 20063027 Investigator-initiated research contract from High Q Foundation, Andrew F. Leuchter, M.D., Principal Investigator. September 01, 2006 – February 28, 2008. $63,048.

“An 8-week, randomized, double-blind, fixed dosage, placebo controlled, parallel-group, multi-center study of the efficacy, safety and tolerability of agomelatine 25 mg and 50 mg in the treatment of Major Depressive Disorder (MDD) followed by a 52-week, open-label extension (CAGO178A2302E)” Multi-site industry sponsored research contract with Novartis Pharmaceuticals.Andrew F. Leuchter, M.D., Principal Investigator. November 01, 2006 – October 31, 2007. $246,916.

“A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of ERPs in Patients with Idiopathic Parkinson’s Disease and End-of-Dose Wearing Off” Multi-site industry sponsored research contract with Novartis Pharmaceuticals. Andrew F. Leuchter, M.D., Principal Investigator. December 15, 2007 – 7/29/09. $209,190.

“Flexible Dosed Duloxetine versus Placebo in the Treatment of Fibromyalgia” Industry-initiated research contract from Eli Lilly & Company. Andrew Leuchter, M.D., Principal Investigator. April 29, 2008 – June 9, 2010. $133,216.

“A Double-Blind Study of Atomoxetine Hydrochloride versus Placebo for the Treatment of ADHD in Young Adults with Assessment of Associated Functional Outcome.” Research contract with Eli Lilly and Company. October 12, 2007 – July 14, 2009. $91,476.39.

“Research Training. Psychobiological Sciences.” T32 MH17140. Andrew Leuchter, M.D., Principal Investigator. July 1, 2008 – June 30, 2013. $1,472,558.

“Brain Mechanisms and Targeting Insomnia in Major Depression” Ian A. Cook, MD, Principal Investigator. Research contract with Sepracor, Inc. March 15, 2008 – March 14, 2010. Role: Co-investigator.

“Personalized Response Indicators of SSRI Effectiveness in Major Depression (PRISE-MD)” 1R01MH085925–01. Ian A. Cook, M.D., Principal Investigator. April 1, 2009 – March 31, 2012. $1,155,000. Role: Consultant.

Supplement to “Personalized Response Indicators of SSRI Effectiveness in Major Depression (PRISE-MD)” 1R01MH085925–01. Ian A. Cook, M.D., Principal Investigator. September 15, 2010 – March 31, 2012. $124,569. Role: Co-investigator.

“Detecting Antidepressant Response Trajectory Shapes in the STAR*D Cohort (DARTS)” 1R34MH085933-01. Aimee M. Hunter, Ph.D., Principal Investigator. April 1, 2009 – March 31, 2010. $192,500. Role: Co-investigator.

“Neurophysiologic Biomarkers for Cognitive and Functional Difficulties after Adjuvant Therapy in Breast Cancer Survivors” Seed grant from the Jonsson Cancer Center Foundation. Andrew Leuchter, M.D., Principal Investigator. April 1, 2011 – March 31, 2012. $29,855.

“Early Changes in Gene Expression as a Predictor of Antidepressant Treatment Response” Seed grant from the Integrated Mood Disorders Study Center at UCLA. Andrew Leuchter, M.D., Principal Investigator. March 1, 2010 – February 28, 2012. $30,000

“Biomarkers for Outcomes in Late-Life Depression (BOLD)” 1RC1MH088438-01. Ian A. Cook, M.D., Principal Investigator. September 30, 2009 – September 29, 2011, $331,409. Role: Co-investigator.

“A Randomized, Double- Blind, Placebo- Controlled, Parallel- Group Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of STX1” Research contract with Seaside Therapeutics, Inc. Andrew Leuchter, M.D., Principal Investigator. September 1, 2010 – August 31, 2011. $99,891.

“Trigeminal Nerve Stimulation for Depression: Dose Finding” Research contract with NeuroSigma, Inc. Andrew Leuchter, M.D., Principal Investigator. July 27, 2011 – July 26, 2013. $159,832.

“Trigeminal Nerve Stimulation for PTSD and Depression” Research contract with NeuroSigma, Inc. Andrew Leuchter, M.D., Principal Investigator. August 23, 2011 – August 22, 2013. $42,300.

“Neuromodulation as a New Treatment for Post-Traumatic Stress Disorder in Veterans: Evaluating the

Effectiveness of Trigeminal Nerve Stimulation” Research contract with the Department of the Army: US Army Medical Research Acquisition. Andrew Leuchter, M.D., Principal Investigator. April 1, 2014 – February 28, 2018. 12041006 (Leuchter), Award#: W81XWH-14-2-0125. $2,155,692.

PATENTS:

  1. S. Patent: Diagnosing brain conditions by quantitative electroencephalography. Inventors: Leuchter AF, Cook IA. U.S. Patent Number 5,230,346.
  2. S. Patent: Determining the nature of brain lesions by electroencephalography. Inventors: Leuchter AF, Cook IA. U.S. Patent Number 5,269,315.
  3. S. Patent: Method and apparatus for determining the nature of brain lesions by electroencephalography. Inventors: Leuchter AF, Cook IA. U.S. Patent Number 5,309,923.

RESEARCH PAPERS:

  1. Leuchter AF: The responsibilities for the state for the prevention and treatment of mental illness among prisoners. Journal of Forensic Sciences 1981; 26:134
  2. Leuchter AF, Spar JE: The late-onset psychoses: clinical and diagnostic features. Journal of Nervous and Mental Disease 1985; 173(8):488
  3. Leuchter AF: Assessment and treatment of the late –onset psychoses. Hospital and Community Psychiatry 1985; 36(8): 815-816.818
  4. Leuchter AF, Spar JE, Walter DO, and Weiner H: Electroencephalographic spectra and coherence in the diagnosis of Alzheimer’s-type and multi-infarct dementia: a pilot study. Archives of General Psychiatry 1987; 44(11):993-998
  5. Leuchter AF, Walter DO: Topography of brain electrical activity in Alzheimer’s disease. Bulletin of Clinical Neurosciences 1988; 53:78-83
  6. Leuchter AF, Walter DO: Diagnosis and assessment of dementia using functional brain imaging. International Psychogeriatrics 1989; 1:63-72
  7. Leuchter AF, Read S, Walter DO, Shapira J, and Smith C: Stable bimodal response to cholinomimetic drugs in Alzheimer’s disease: brain mapping correlates. Neuropsychopharmacology 1991; 4:165-173
  8. Leuchter AF, Jacobson SA: Quantitative measurement of brain electrical activity in delirium. International Psychogeriatrics 1991; 3:231-247
  9. Leuchter AF, Newton TF, Cook IA, Walter DO, Rosenberg-Thompson S, Lachenbruch PA: Changes in brain functional connectivity in Alzheimer’s-type and infarct dementia. Brain 1992; 115:1543-1561
  10. Newton TF, Leuchter AF, Walter DO, Van Gorp W, Stern C, Mandelkern M, Weiner H: EEG coherence in men with AIDS: association with subcortical metabolic activity. Journal of Neuropsychiatry and Clinical Neurosciences 1993; 5(3): 316-321
  11. Jacobson S, Leuchter AF, Walter D: Conventional and quantitative EEG in the diagnosis of delirium among the elderly. Journal of Neurology, Neurosurgery and Psychiatry 1993; 56:153-158
  12. Small GW, Leuchter AF, Mandelkern MA, LaRue A, Okonek A, Lufkin RB, Jarvik LF, Matsuyama SS, Bondareff W: Clinical, neuroimaging, and environmental risk differences in monozygotic female twins appearing discordant for dementia of the Alzheimer type. Archives of Neurology 1993; 50:209-219
  13. Leuchter AF, Daly KA, Rosenberg-Thompson S, Abrams M: The prevalence of electroencephalographic abnormalities among patients with possible organic mental syndromes. Journal of the American Geriatric Society 1993; 41:605-611
  14. Jacobson S, Leuchter AF, Walter DO, Weiner H: Serial quantitative EEG among elderly subjects with delirium. Biological Psychiatry 1993; 34:135-140
  15. Leuchter AF, Cook IA, Newton TF, Walter DO, Rosenberg-Thompson S, Lachenbruch PA, Weiner H: Regional differences in brain electrical activity in dementia: use of spectral power and spectral ratio measures. Electroencephalography and Clinical Neurophysiology 1993; 87:385-389
  16. Leuchter A, Simon SL, Daly, KA, Abrams M, Rosenberg-Thompson S, Dunkin JJ, Cook IA, Newton TF, Spar JE: Quantitative EEG Correlates of Outcome in Older Psychiatric Patients Part II: Two-Year Follow-Up of Patients With Depression American Journal of Geriatric Psychiatry 1993; 2(4)
  17. Newton TF, Leuchter AF, Miller EM, Weiner H: Quantitative EEG in patients with AIDS and asymptotic HIV infection. Clinical EEG 1994; 25:18-25
  18. Dunkin JJ, Leuchter AF, Newton T, Cook, IA: Reduced EEG coherence in dementia: state or trait marker? Biological Psychiatry 1994; 35:870-879
  19. Leuchter AF, Cook IA, Lufkin RB, Dunkin J, Newton TF, Cummings JL, Mackey K, Walter D: Cordance: A new method for assessment of cerebral perfusion and metabolism using quantitative electroencephalography. Neuroimage 1994; 1:208-219
  20. Leuchter AF, Dunkin J, Lufkin R, Anzai Y, Newton T: The effect of white-matter disease on functional connections in the aging brain. Journal of Neurology, Neurosurgery and Psychiatry 1994; 57:1347-1354
  21. Leuchter AF, Cook IA, Mena I, Dunkin J, Cummings JL, Newton, T, Migneco O, Lufkin R, Walter D, Lachenbruch P: Assessment of cerebral perfusion using quantitative EEG cordance. Psychiatry Research: Neuroimaging 1994; 55:141-152
  22. Leuchter AF, Simon SL, Daly KA, Rosenberg-Thompson S, Abrams M, Dunkin JJ, Cook IA, Newton TF, Walter DO, Cummings JL: Quantitative EEG correlates of outcome in elderly psychiatric patients. I. Cross-sectional and longitudinal assessment of patients with dementia. American Journal of Geriatric Psychiatry 1994; 2:200-209
  23. Leuchter AF, Simon SL, Daly KA, Abrams M, Rosenberg-Thompson S, Dunkin JJ, Cook IA, Newton TF, Spar JE: Quantitative EEG correlates of outcome in elderly psychiatric patients. II. Two–year follow-up of patients with depression. American Journal of Geriatric Psychiatry 1994; 2:290-299
  24. Newton TF, Leuchter AF, Walter D, Van Gorp W, Morgenstern H, Miller E, Lieb K, Visscher B, Satz P, Weiner H: Electroencephalographic coherence in acquired immune deficiency syndrome. Psychiatry Research 1994; 54:1-11
  25. Dunkin JJ, Osato S, Leuchter AF: Relationships between EEG coherence and neuropsychological test in dementia. Clinical EEG 1995; 26(1):47-59
  26. Holschneider D, Leuchter AF: Beta activity in aging and dementia. Brain Topography 1995; 8(2):169-180
  27. Cook IA, Leuchter AF: Synaptic dysfunction in Alzheimer’s disease: clinical assessment using quantitative EEG. Brain and Behavioral Research 1996; 78:15-23
  28. Yener GG, Leuchter AF, Jenden D, Read SL, Cummings JL, Miller BL: Quantitative EEG in fronto-temporal dementias. Clinical EEG 1996; 27(2):61-68
  29. Holschneider DP, Leuchter AF, Uijtdehaage SH, Abrams M, Rosenberg-Thompson S: Loss of high-frequency EEG response to thiopental in Alzheimer’s dementia. Neuropsychopharmacology 1997; 20:1-7
  30. Leuchter AF, Cook IA, Uijtdehaage SH, Lufkin RB, Anderson-Hanley C, Abrams M, Rosenberg-Thompson S, O’Hara R, Simon SL, Babaie AB: Brain structure and function, and the outcomes of treatment for depression. Journal of Clinical Psychiatry 1997; 55[suppl 16]:22-31
  31. Newton TF, Leuchter AF: EEG power correlates with subcortical metabolic activity in AIDS. Journal of Neuropsychiatry and Clinical Neurosciences 1997; 9:974-978
  32. Holschneider DP, Leuchter AF, Walton NY, Scremin OU, Treiman DM: Changes in cortical EEG and cholinergic function in response to NGF in rats with nucleus basalis lesions. Brain Research 1997; 765:228-237
  33. Cook IA, Leuchter AF, Uijtdehaage SH, Holschneider D, Osato S, Abrams M, Rosenberg-Thomson S: Altered cerebral energy utilization in late life depression. Journal of Affective Disorders 1998; 49(2): 89-99
  34. Holschneider DP, Leuchter AF, Scremin OU, Treiman DM, Walton NY: Changes in brain electrical coherence in response to NGF in rats with nucleus basalis lesions. Brain Research Bulletin 1998; 45:531-541
  35. Cook IA, O’Hara R, Uijtdehaage SH, Mandelkern M, Leuchter AF: Assessing the accuracy of topographic EEG mapping for determining local brain function. EEG Clin Neurophys 1998; 107:408-414
  36. Leuchter AF, Uijtdehaage SH, Cook IA, O’Hara R, Mandelkern M: Relationship between brain electrical activity and cortical perfusion in normal subjects: Psychiatry Research: Neuroimaging1999;90:125-140
  37. Cook IA, Leuchter AF, Witte E, Abrams M, Uijtdehaage SHJ, Stubbeman W, Rosenberg-Thompson S, Anderson-Hanley C: Neurophysiologic predictors of treatment response to fluoxetine in major depression. 1999; Psychiatry Research 85:263-273
  38. Holschneider DP, Waite JJ, Leuchter AF, Walton NY, Scremin OU: Changes in electrocortical power coherence in response to the cholinergic toxin 192 IgG-saporin. Experimental Brain Research 1999; 126:270-280
  39. Cohen CI, Cohen GD, Blank K, Gaitz C, Katz IR, Leuchter A, Maletta G, Meyers B, Sakauye K, Shamoian C: Schizophrenia and older adults: An overview: Directions for research and policy American Journal of Geriatric Psychiatry 1999; 8(1): 19-28
  40. Dunkin JJ, Leuchter AF, Cook IA, Kasl-Godley JE, Abrams M, Rosenberg-Thompson S: Executive dysfunction predicts non-response to fluoxetine in major depression. Journal of Affective Disorders2000; 60:13-23
  41. Holschneider DP, Leuchter AF: Attenuation of brain high frequency electrocortical response after thiopental in early stages of Alzheimer’s dementia. Psychopharmacology 2000; 149:6-11
  42. Edwards-Lee T, Cook IA, Fairbanks L, Leuchter AF, Cummings JL: Quantitative electroencephalographic correlates of psychosis in Alzheimer Disease. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 2000; 13: 163-170
  43. Cook IA, Leuchter AF: Prefrontal changes and treatment response prediction in depression. Seminars in Clinical Neuropsychiatry 2001; 6:113-120
  44. Leuchter AF, Cook IA, Witte EA, Morgan ML, Abrams M: Changes in brain function of depressed subjects during treatment with placebo. American Journal of Psychiatry 2002; 159:122-129
  45. Cook IA, Morgan ML, Dunkin JJ, David S, Witte E, Lufkin R, Abrams M, Rosenberg S, Leuchter AF.Estrogen replacement therapy is associated with less progression of subclinical structural brain disease in normal elderly women: A pilot study. International Journal of Geriatric Psychiatry 2002; 17: 610-618
  46. Cook IA, Leuchter AF, Witte EA, Stubbeman WF, Abrams M, Rosenberg S: Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 2002; 27:120-131
  47. Cook IA, Leuchter AF, Morgan M, Witte EA, David S, Lufkin R, Babaie A, Dunkin J, O’Hara R, Simon S, Lightner A, Thomas S, Broumandi D, Badjatia N, Mickes L, Mody R, Arroyo S, Zheng Z, Abrams M, Rosenberg S: Cognitive and physiologic correlates of subclinical structural brain disease in elderly normal controls. Archives of Neurology 2002; 59:1612-1620
  48. Newton TF, Cook IA, Kalechstein AD, Duran S, Monroy F, Ling W, Leuchter AF: Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals. Clinical Neurophysiology 2003; 114:410-415
  49. Cook IA, Leuchter AF, Morgan ML, Dunkin JJ, Witte E, David S, Mickes L, O’Hara R, Simon S, Lufkin R, Abrams M, Rosenberg S: Longitudinal progression of subclinical structural brain disease in normal aging. American Journal of Geriatric Psychiatry 2004; 12:190-201
  50. Newton TF, Kalechstein AD, Hardy DJ, Cook IA, Nestor L, Ling W, Leuchter AF. Association between quantitative EEG and neurocognition in methamphetamine dependent volunteers. Clinical Neurophysiology 2004; 115:194-198
  51. Leuchter AF, Morgan ML, Cook IA, Dunkin J, Abrams M, Witte E: Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacology 2004; 177:15-22
  52. Marie-Mitchell A, Leuchter AF, Chou C, Gauderman WJ, Azen SP: Predictors of treatment outcome in antidepressant clinical trials. Psychiatry Research 2004; 127:73-84
  53. Krell HV, Leuchter AF, Morgan M, Cook IA, Abrams M: Subject expectations and outcome of treatment with an experimental antidepressant. The Journal of Clinical Psychiatry 2004; 65:1174-1179
  1. Stubbeman WF, Leuchter AF, Cook IA, Shurman BD, Gunay I, Gonzalez S: Neurophysiologic prediction of ECT response in depression. Journal of ECT 2004; 20:142-144
  2. Morgan ML, Witte EA, Cook IA, Leuchter AF, Abrams M, Siegman B: Influence of age, gender, health status, and depression on quantitative EEG. Neuropsychobiology 2005; 52:71-76
  3. Cook IA, Leuchter AF, Morgan ML, Stubbeman WF, Siegman B, Abrams M: Changes in prefrontal activity characterize clinical response in treatment resistant depression. Journal of Psychiatric Research 2005; 39:461-466
  4. Hunter AM, Leuchter AF, Morgan ML, Cook IA, Abrams M, Siegman B, DeBrota DJ, Potter WZ: Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo. Neuropsychopharmacology 2005; 30:792-799
  5. Krell HV, Leuchter AF, Cook IA, Abrams M: Evaluation of reboxetine, a noradrenergic antidepressant on the treatment of fibromyalgia and chronic low back pain. Psychosomatics 2005; 47:1-6
  1. Morgan ML, Cook IA, Rapkin AJ, VanBatenburg C, Leuchter AF: Estrogen augmentation in perimenopausal depression: a pilot study. Journal of Clinical Psychiatry 2005; 66:774-780
  2. Lesser IM, Leuchter AF, Trivedi MH, Davis LL, Wisniewski S, Petersen T, Stegman D, Rush AJ: Characteristics of insured and non-insured depressed outpatients: preliminary findings from STAR*D. Psychiatric Services 2005; 56:995-1004
  3. Moses T, Leuchter AF, Cook IA, Abrams M: Does the clinical course of depression determine improvement in symptoms and quality of life? Journal of Nervous and Mental Disease 2006; 194:241-248
  4. Venneman S, Leuchter AF, Bartzokis G, Beckson M, Simon SL, Schaefer M, Rawson R, Newton T, Cook IA, Uijtdehaage S, Ling W: Variation in neurophysiological function and evidence of quantitative electroencephalogram discordance: predicting cocaine-dependent treatment attrition. Journal of Neuropsychiatry and Clinical Neuroscience 2006; 18(2):208-16
  5. Morgan ML, Cook IA, Rapkin AJ, Leuchter AF: Neurophysiologic changes during estrogen augmentation in perimenopausal depression. Maturitas 2007; 56(1):54-60
  6. Hunter AM, Leuchter AF, Morgan ML, Cook IA: Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. American Journal of Psychiatry 2006; 163(8):1426-32
  7. Claassen CA, Trivedi MH, Rush JA, Husain MM, Zisook S, Young E, Leuchter AF, Wisniewski SR, Balasubramani GK, Alpert J: Clinical differences among depressed patients with and without a history of suicde attempts: findings from the STAR*D trial. Journal of Affective Disorders 2007; 97:77-84
  8. Cook IA, Bookheimer SY, Mickes L, Leuchter AF, Kumar A. Aging and brain activation with working memory tasks: an fMRI study of connectivity. International Journal of Geriatric Psychiatry 2007; 22(4):332-42
  9. Hunter AM, Cook IA, Leuchter AF: The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in Major Depressive Disorder. Psychiatric Clinics of North America 2007; 30(1):105-124
  10. Lesser IM, Leuchter AF, Trivedi MH, Davis LL, Wisniewski SR, Balasubramani GK, Fava M, Rush AJ: Insured and non-insured depressed outpatients: how do they compare? Annals of Clinical Psychiatry2007; 19(2):73-82
  11. Shapiro D, Cook IA, Davydov DM, Ottaviani C, Leuchter AF, Abrams M: Yoga as a complementary treatment of depression: effects of traits and moods on treatment outcome. Evidence Based Complementary and Alternative Medicine 2007; 4(4):493-502
  12. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, Biggs MM, Zisook S, Leuchter AF, Howland R, Warden D, Trivedi MH: Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. American Journal of Psychiatry 2008; 10:1176
  13. Cook IA, Pajot SK, Leuchter AF: Ancient architectural resonance patterns and regional brain activity. Time and Mind 2008; 1(1):95-107
  14. Leuchter AF, Cook IA, DeBrota DJ, Hunter AM, Potter WZ, McGrouther CC, Morgan ML, Abrams M, Siegman B. Changes in brain function during administration of venlafaxine or placebo to normal subjects. Clinical EEG & Neuroscience 2008; 39(4):175-81
  15. Korb AS, Cook IA, Hunter AM, Leuchter AF: Brain electrical source differences between depressed subjects and healthy controls. Brain Topography 2008; 21(2):138-46
  16. Leuchter AF, Lesser IM, Trivedi MH, Rush AJ, Morris DW, Warden D, Fava M, Wisniewski SR, Luther JF, Perales M, Gaynes BN, Stewart JW: An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with Major Depressive Disorder. Journal of Psychiatric Practice 2008; 14(5):271-80
  17. Hunter AM, Ravikumar S, Cook IA, Leuchter AF: Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression. Acta Psychiatrica Scandnavica 2009; 119(4):266-273
  18. Leuchter AF, Cook IA, Hunter AM, Korb AS: Use of clinical neurophysiology for the selection of medication in the treatment of Major Depressive Disorder: the state of the evidence. Clinical EEG & Neuroscience 2009; 40(2):78-83
  19. Hunter AM, Leuchter AF, Cook IA, Abrams M, Siegman BE, Furst DE, Chappell AS: Brain functional changes and duloxetine treatment response in fibromyalgia. Pain Medicine; 10(4):730-8
  20. Korb AS, Hunter AM, Cook IA, Leuchter AF: Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in Major Depression. Clinical Neurophysiology 2009; 120(7):1313-9
  21. Leuchter AF, McCracken JT, Hunter AM, Cook IA, Alpert JE: MAO-A and COMT functional polymorphisms and the placebo response in Major Depressive Disorder. Journal of Clinical Psychopharmacology 2009; 29(4):372-377
  22. Leuchter AF, Cook IA, Marangell LB, Gilmer WS, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, McCracken JT, Fava M, Iosifescu D, Greenwald S: Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. Psychiatry Research 2009; 169:124-131
  23. Leuchter AF, Cook IA, Gilmer WS, Marangell LB, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Fava M, Iosifescu D, Greenwald S: Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in Major Depressive Disorder. Psychiatry Research 2009; 169:132-138
  24. Kalechstein AD, De La Garza R, Newton TF, Green MF, Cook IA, Leuchter AF: Quantitative EEG abnormalities are associated with memory impairment in recently abstinent methamphetamine-dependent individuals. Journal of Neuropsychiatry and Clinical Neurosciences 2009; 21:254-258
  25. Cook IA, Hunter AM, Abrams M, Siegman B, Leuchter AF: Midline and right frontal brain function as a physiologic biomarker of remission in major depression. Psychiatry Research: Neuroimaging 2009; 174(2):152-7
  26. Hunter AM, Muthen BO, Cook IA, Leuchter AF: Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in Major Depressive Disorder. J Psychiatry Research2009; 44(2):90-98
  27. Leuchter AF, Cook IA, Hunter AM, Korb AS: A new paradigm for the prediction of antidepressant treatment response. Dialogues in Clinical Neuroscience 2009; 11(4):435-46
  28. Farahbod H, Cook IA, Korb AS, Hunter AM, Leuchter AF: Amygdala lateralization at rest and during viewing of neutral faces in major depressive disorder using low-resolution brain electromagnetic tomography. Clinical EEG and Neuroscience Journal 2010; 41(1):19-23
  29. Leuchter AF, Husain MM, Cook IA, Trivedi MH, Wisniewski SR, Gilmer W, Luther JF, Fava M, Rush AJ: Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D report. Psychological Medicine 2010; 40(2):239-252
  30. Kobak KA, Leuchter A, DeBrota D, Engelhardt N, Williams JB, Cook IA, Leon AC, Alpert J: Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response. Journal of Clinical Psychopharmacology 2010; 30(20):193-197
  31. Hunter AM, Leuchter AF, Cook IA, Abrams M: Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment. Acta Psychiatrica Scandinavica 2010; 1-9
  32. Warden D, Trivedi MH, Wisniewski SR, Friedman ES, Leuchter AF, Kornstein S, Kurian B, Fava M, Zisook S, Miyahara S, Rush AJ: Early adverse events and attrition in SSRI treatment: a suicide methodology study (SAMS) report. Journal of Clinical Psychopharmacology 2010; 30:259-266
  33. Leuchter AF, Cook IA, Hamilton SP, Narr KL, Toga A, Hunter AM, Faull K, Whitelegge J, Andrew AM, Loo J, Way B, Nelson SF, Horvath S, Lebowitz BD: Biomarkers to predict antidepressant treatment response. Current Psychiatry Reports 2010;12:553–562
  34. Hunter AM, Cook IA, Leuchter AF: Impact of antidepressant treatment history on clinical outcomes in placebo and medication treatment of Major Depression. Journal of Clinical Psychopharmacology2010; 30(6):748-751
  35. Hunter AM, Bordelon YM, Cook IA, Leuchter, AF: Quantitative electroencephalographic measures in Huntington’s Disease: a pilot study. PLoS Currents: Huntington Disease 2010; RRN1192
  36. Rabinoff M, Kitchen CMR, Cook IA, Leuchter AF: Evaluation of quantitative EEG by classification and regression trees to characterize responders to antidepressant and placebo treatment. The Open Medical Informatics Journal. 2011; 5:1-8
  37. Cook IA, Warren C, Pajot SK, Schairer D, Leuchter AF: Regional brain activation with advertising images. Journal of Neuroscience, Psychology, and Economics 2011;4(3):147-160
  38. Muthen B, Asparouhov T, Hunter AM, Leuchter AF: Growth mixture modeling with possibly non-ignorable dropout: alternative analyses of the STAR*D antidepressant trial. Psychological Methods2011;16(1):17-33
  39. Korb AS, Hunter AM, Cook IA, Leuchter AF: Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder. Psychiatry Research: Neuroimaging 2011; 192(3):188-194
  40. Hunter AM, Cook IA, Greenwald S, Tran ML, Miyamoto K, Leuchter AF: The Antidepressant Treatment Response (ATR) index and treatment outcomes in a placebo-controlled trial of fluoxetine. Journal of Clinical Neurophysiology 2011;28(5):478-482
  41. Kerber KB, Wisniewski SR, Luther JF, Leuchter AF, D’Empaire I, Trivedi MH, Rush AJ: Effects of heart disease on depression treatment: results from the COMED Study. General Hospital Psychiatry 2012; 34(1):24-34
  42. Leuchter AF, Cook IA, Hunter AM, Cai C, Horvath S: Resting-state quantitative electroencephalography reveals increased neurophysiologic connectivity in depression. PLoS ONE2012; 7(2):1
  43. Hunter AM, Cook IA, Leuchter AF: Does prior antidepressant treatment of major depression impact brain function during current treatment? European Neuropsychopharmacology 2012; (10): 711-720
  44. Cook IA, Hunter AM, Gilmer WS, Iosifescu DV, Zisook S, Burgoyne KS, Howland RH, Trivedi MH, Jain R, Greenwald S, Leuchter AF: Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: A report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial. Journal of Clinical Psychiatry 2013; 74(1):51-56
  1. Hunter, AM, Cook, IA, Abrams, M, Leuchter, AF: Neurophysiologic effects of repeated exposure to antidepressant medication: Are brain functional changes during antidepressant administration influenced by learning processes? Medical Hypotheses 81(6):1004-1011
  2. Jain FA, Hunter AM, Brooks JO 3rd, Leuchter AF: Predictive Socioeconomic and clinical profiles of antidepressant response and remission. Depression and Anxiety 2013; 30(7):624-630
  3. Cook IA, Schrader LM, DeGiorgio CM, Miller PR, Maremont ER, Leuchter AF: Trigeminal nerve stimulation in major depressive disorder: acute outcomes in an open pilot study. Epilepsy & Behavior2013; 28:221-226
  4. Ercoli LM, Castellon SA, Hunter AM, Kwan L, Kahn-Mills BA, Cernin PA, Leuchter AF, Ganz PA: Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints. Brain Imaging and Behavior 2013; 7(4):543-553
  5. Leuchter AF, Cook IA, Jin Y, Phillips B: The relationship between brain oscillatory activity and therapeutic effectiveness of transcranial magnetic stimulation in the treatment of major depressive disorder. Frontiers in Human Neuroscience 2013; 7(37)1-12
  6. Hunter AM, Korb AS, Cook IA, Leuchter AF: Rostral anterior cingulate activity in major depressive disorder: state or trait marker of responsiveness to medication? The Journal of Neuropsychiatry and Clinical Neurosciences 2013; 25(2):126-133
  7. Hunter AM, Leuchter AF, Power RA, Muthén B, McGrath PJ, Lewis CM, Cook IA, Garriock HA, McGuffin P, Uher R, Hamilton SP: A genome-wide association study of a sustained pattern of antidepressant response. Journal of Psychiatric Research 2013; 47(9):1157-1165
  8. Cook IA, Espinoza R, Leuchter AF: Neuromodulation for depression: invasive and noninvasive (deep brain stimulation, transcranial magnetic stimulation, trigeminal nerve stimulation). Neurosurgery Clinics of North America 2014; 25:103–116
  9. Hunter AM, Kwan L, Ercoli LM, Mills BL, Cook IA, Ganz PA, Leuchter AF: Quantitative electroencephalography biomarkers of cognitive complaints after adjuvant therapy in breast cancer survivors: a pilot stydy. Psycho-Oncology 2014; 23(6); 713-715
  10. Jain FA, Cook IA, Leuchter AF, Hunter AM, Davydov DM, Ottaviani C, Tartter M, Crump C, Shapiro D: Heart rate variability and treatment outcome in major depression: a pilot study. International Journal Psychophysiology 2014; 93(2):204-210
  11. Cook IA, Hunter AM, Korb AS, Leuchter AF: Do prefrontal midline electrodes provide unique neurophysiologic information in major depressive disorder? Journal of Psychiatric Research 2014; 53:69-75
  12. Leuchter AF, McGough JJ, Korb AS, Hunter AM, Glaser PE, Deldar A, Durell TM, Cook IA: Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project. Journal of Psychiatric Research 2014; 54:11-8
  13. Leuchter AF, Hunter AM, Tartter M, Cook IA: Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression. British Journal of Psychiatry 2014; 205(6):443-9
  14. Caudill M, Hunter AM, Cook IA, Leuchter AF: The antidepressant treatment response (ATR) index and reboxetine treatment outcome in major depressive disorder. Clinical EEG and Neuroscience2014; DOI: 10.1177/1550059414532443
  15. Leuchter AF, Hunter AM, Krantz DE, Cook IA: Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder. Dialogues in Clinical Neuroscience 2014; 16(4):525-37
  16. McGough JJ, Loo SK, Sturm A, Cowen J, Leuchter AF, Cook IA: An eight-week, open-trial, pilot feasibility study of trigeminal nerve stimulation in youth with attention deficit/hyperactivity Brain Stimulation 2015; 8(2):299-304
  17. Leuchter AF, Hunter AM, Krantz, DE, Cook IA: Rhythms and blues: modulation of oscillatory synchrony and the mechanism of action of antidepressant treatments. Annals of the New York Academy of Sciences 2015; 1344:78-91
  18. Ercoli LM, Petersen L, Hunter AM, Castellon SA, Kwan L, Kahn-Mills BA, Embree LM, Cernin PA, Leuchter AF, Ganz PA: Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psychooncology 2015; doi: 10.1002/pon.3769
  19. Leuchter AF, Cook IA, Feifel D, Goethe JW, Husain M, Carpenter LL, Thase ME, Krystal AD, Philip NS, Bhati MT, Burke WJ, Howland RH, Sheline YI, Aaronson ST, Iosifescu DV, O’Reardon JP, Gilmer WS, Jain R, Burgoyne KS, Phillips B, Manberg PJ, Massaro J, Hunter AM, Lisanby SH, George MS: Efficacy and safety of low-field synchronized transcranial magnetic stimulation (sTMS) for treatment of major depression. Brain Stimulation 2015; 8(4):787-94
  20. McGrath P, Nunes EV, Hasin D, Stewart JW, Chen Y, Jiang H, Thase M, Kornstein SG, Leuchter AF, Davis L, Rush AJ: Recovery from major depression in patients with concurrent alcohol use disorders: a STAR*D report. (in submission)
  21. Hunter AM, Cook IA, Tartter M, Sharma SK, Disse GD, Leuchter AF: Antidepressant treatment history and drug-placebo separation in a placebo-controlled trial in major depressive disorder. Psychopharmacology 2015; 232(20):3833-40
  22. Koek RJ, Schwartz HN, Scully S, Langevin JP, Spangler S, Korotinsky A, Jou K, Leuchter AF: Treatment-refractory posttraumatic stress disorder (TRPTSD): A review and framework for the future. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2015; (in submission)

MONOGRAPHS

Leuchter AF, Reynolds CF, Katz IR, Alexopoulos GS, Lebowitz BD: Late-Life
Depression: Recent Advances in Assessment and Treatment. Proceedings of a symposium held at the Institute on Psychiatric Services meeting in Boston, MA on October 8, 1995.

Leuchter AF, Bruce ML, Frazer A, Roose SP, Borson S: Medication Treatment
Outcomes in Geriatric Depression: Does Mechanism of Action Make a Difference? CME clinical symposium update from the 1999 American Association for Geriatric Psychiatry Annual Meeting in New Orleans, LA on March 14-17, 1999.

Editor-in-Chief: Minds & Medicine: The Role of New Antipsychotics in the Treatment of Bipolar Disorder. Convened at the American College of Neuropsychopharmacology in San Juan, Puerto Rico on December 08, 2003.

Editor-in-Chief: Minds & Medicine: Impact of Atypical Antipsychotics on Functional Recovery and Long-term Outcomes. Convened at the American Psychiatric Association Annual Meeting in New York, New York on May 05, 2004.

Editor-in-Chief: Minds & Medicine: Managing Antipsychotic-related Metabolic Effects in Individuals with Mental Illness. Convened at the American College of Neurospychopharmacology Annual Meeting in San Juan, Puerto Rico on December 14, 2004.

Editor-in-Chief: Minds & Medicine: Treatment Advances in Chronic Neuropathic Pain. Proceedings from the UCLA Minds & Medicine Editorial Meeting in Palm Springs, California on February 24, 2005.

BOOK CHAPTERS

  1. Leuchter AF, Jarvik LF. Drug treatment of dementia. In Burrows GD (ed.), Anticonvulsants, and Other Drugs in Psychiatry, vol. 4. Amsterdam: Elsevier, pp. 371-384, 1987.
  2. Leuchter AF, Daly K. Treatment of psychosis. In: Samiy, A.H., Douglas, R.G. and Barondess, J.A. (eds.), 1989. Textbook of Diagnostic Medicine. Philadelphia, Pa: Lea & Febiger.
  3. Leuchter AF, Garcia M. Neuroimaging in the elderly with chronic mental illness. In Light E, Lebowitz B (eds.), The Chronic Mentally Ill Elderly: Directions for Research. Washington, DC: American Psychiatric Press, pp. 145-166, 1991.
  4. Leuchter AF. Electroencephalography. In Sadavoy J, Lazarus L, Jarvik L (eds.), Comprehensive review of Geriatric Psychiatry. Washington, DC: American
    Psychiatric Press, pp. 273-283, 1991.
  5. Leuchter AF. Brain structural and functional correlates of late-life depression. In Lebowitz B, Schneider L (eds.), Diagnosis and Treatment of Depression in Late-Life. Washington, DC: American Psychiatric Press, pp. 117-130, 1994.
  6. Leuchter AF, Holschneider D. Quantitative electroencephalography: neurophysiological alterations in normal aging and geriatric neuropsychiatric disorders. In Coffey E, Cummings J (eds.), Textbook of Geriatric Neuropsychiatry. Washington, DC: American Psychiatric Press, pp. 215-240, 1994.
  7. Cook IA, Leuchter AF. Structural and functional brain disturbances in geriatric depression. In Finkel SI, Bergener M (eds.), Treating Alzheimer’s and Other Dementias: Clinical Applications of Recent Research Advances. New York: Springer Publishing Co., pp.358-369, 1995.
  8. Leuchter AF. Geriatric psychiatry: neuroimaging. In Kaplan HI, Sadock BJ (eds.), Comprehensive Textbook of Psychiatry, VI. Baltimore: Williams & Wilkins Company, 1995.
  9. Jacobson SA, Leuchter AF. Delirium. In Reichman WE, Katz PR (eds.), Psychiatric Care in the Nursing Home. New York: Oxford University Press, 1996.
  10. Leuchter AF, Holschneider D. Electroencephalography. In Sadavoy J, Lazarus L, Jarvik L (eds.), Comprehensive Review of Geriatric Psychiatry-II. Washington, DC: American Psychiatric Press, 1996.
  11. Leuchter, AF. Indications for neuroimaging. In Ames D, Chui E (eds.), Neuroimaging and the Psychiatry of Late Life. New York: Cambridge University Press, 1997.
  12. Leuchter AF, Cook IA. Electroencephalography and magnetoencephalography. In Ames D, Chui E (eds.), Neuroimaging and the Psychiatry of Late Life. New York: Cambridge University Press, 1997.
  13. Walter DO, Leuchter AF. A tutorial on classical computer analysis of EEGs: spectra and coherences. In Butler S, Angeleri F, Giaquinto S, Majkowski J (eds.), Analysis of the Electrical Activity of the Brain. New York: John Wiley & Sons, Ltd, 1997.
  14. Leuchter AF, Holschneider D. Quantitative electroencephalography: neurophysiological alterations in normal aging and geriatric neuropsychiatric disorders. In Coffey E, Cummings J (eds.), Textbook of Geriatric Neuropsychiatry, 2nd Washington DC: American Psychiatric Press, 1999.
  15. Leuchter AF, Holschneider D. Electroencephalography. In Sadavoy J, Lazarus L, Jarvik L (eds.), Comprehensive Review of Geriatric Psychiatry- 3rd Edition. Washington, DC: American Psychiatric Press, 2004.
  16. Leuchter AF. Indications for neuroimaging. In Levy R, Ames D, Chiu E (eds.), Neuroimaging and the Psychiatry of Late Life. New York: Cambridge University Press, 2007.
  17. Cook IA, Hunter AM, Korb A, Farahbod H, Leuchter AF. EEG Signals in Psychiatry: Depression. In: S Tong and NV Thakor (eds). Quantitative EEG Analysis: Methods and Applications. Norwood, MA: Artech House Press, 2009.
  18. Muthén, B., Brown, C.H., Hunter, A., Cook, I.A., Leuchter, A.F. General approaches to analysis of course: Applying growth mixture modeling to randomized trials of depression medication. In P.E. Shrout, K.M. Keyes & K. Ornstein (eds.), Causality and Psychopathology: Finding the Determinants of Disorders and Their Cures. New York: Oxford University Press, pp. 159-178, 2011.

BRIEF REPORTS, BOOK REVIEWS, AND LETTER

  1. Leuchter AF. Getting ahead in science. Book review. Contemporary Psychiatry. 2:138, 1983.
  2. Leuchter AF. Practical geriatrics: assessment and treatment of the late-onset psychoses.
    Hospital and Community Psychiatry. 36(8):815, 1985.
  3. Leuchter AF. Late-onset psychoses: differential diagnosis and management. Geriatric Medicine Today. 7:121-129, 1988.
  4. Szuba M, Leuchter AF. Falling backwards in two elderly patients taking bupropion.
    Journal of Clinical Psychiatry. 53:157-159, 1992.
  5. Bystritsky A, Leuchter AF, Vapnik T. EEG abnormalities in non-medicated panic disorder.
    Journal of Nervous and Mental Disease. 187(2):113-4, 1999.
  6. Leuchter AF, Levey GS. Need to strike balance with industry–academia rules. Letter. Nature 449, 658, 2007.
  7. Leuchter AF. Healing the Hardware of the Soul. Book review. American Journal of Psychiatry166:625, 2009.
  8. Leuchter AF, Cook IA. Letter to the Editor: Reply to Kuo and Tsai, Psychiatry Res, 2010. DOI:10.1016/j.psychres.2010.09.001
  9. Leuchter AF, Cook IA, Hunter AM. Letter to the Editor: Comment on ‘The use of the EEG in measuring therapeutic drug action: Focus on depression and antidepressants’ DOI: 10.1177/0269881111430732, 2011
  10. Cook IA, Espinoza R, Leuchter AF. Neuromodulation for depression: invasive and non-invasive (DBS, TMS, TNS). Neurosurgical Clinics of North America. 25:103–116, 2014.
  11. Jain FA, Hunter AM, Leuchter AF, & Brooks, JO (2015). A role for profiles of patient-specific depression characteristics and socioeconomic factors in the prediction of antidepressant treatment outcome. The Journal of Clinical Psychiatry. 76(3): 327, 2014.
  12. Leuchter AF, Hunter AM, Tartter M, Cook IA. Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression. The British Journal of Psychiatry. 205 (6) 443-449, 2014.

ABSTRACTS

  1. Wallick E, Ray V, Anner B, Leuchter A, and Schwartz A: H³-ouabain binding to highly purified Na+, K+-ATPase. Federation Proceedings 34:249, 1975.
  2. Wallick E, Ray V, Leuchter A, and Schwartz A: Chemical modification of purified Na+, K+-ATPase. Federation Proceedings. 35:1663, 1976.
  3. Leuchter AF, Walter DO, Weiner H: Differential diagnosis of dementia using topographic electroencephalography. Journal of Clinical Neurophysiology. 5:328, 1988.
  4. Leuchter AF, Read S, Shapira J, Walter D, Smith C: Computer-analyzed EEG and treatment of Alzheimer’s disease. New Research Program & Abstracts, American Psychiatric Associated 141stAnnual Meeting. P. 63, 1988.
  5. Daly K, Leuchter AF, Rosenberg-Thompson S: The usefulness of electroencephalography in diagnosis of dementia early in the course of illness. Abstract presented at Southern California Regional Meeting. Los Angeles, CA, February 1989.
  6. Leuchter AF, Newton TF, Van Gorp W, Miller E, Weiner H, Freeman D, Evan G, Satz P: Early detection of HIV-effects on brain function. New Research Program and Abstracts, American Psychiatric Associations 142nd Annual Meeting. P. 171, 1989.
  7. Newton TF, Leuchter AF, Walter DO, Lieb K, Weiner H: EEG coherence in AIDS. American Electroencephalographic Society 1990 Annual Meeting and Courses Program. P. 26, 1990.
  8. Newton TF, Leuchter AF, Walter DO, Van Gorp W, Stern C, Mandelkern M, Weiner H: EEG coherence in men with AIDS: association with subcortical metabolic activity. Abstract presented at NIMH training program in HIV disease. Washington, D.C. March 1991.
  9. Mackey JK, Leuchter AF, Cook IA, Lufkin RB, Duerinckx AJ, Walter DO: Lesions on MRI in patients with dementia: correlation with brain functional abnormalities seen in quantitative. EEG Society for Magnetic Resonance Imaging, Chicago, IL, April 31, 1991.
  10. Mackey JK, Leuchter AF, Cook IA, Dunkin JJ, Lufkin RB. “Quantitative three-dimensional correlation of magnetic resonance imaging lesions with brain functional abnormalities in dementia patients.” Radiological Society of North America, Chicago IL 1991.
  11. Leuchter AF, Lufkin RB, Cook IA, Cummings JL, Ross GW, Mackey K: Electrophysiologic detection of deep white-matter ischemic disease in the elderly. Book of Abstracts, Proceedings of the Fifth Congress of the International Psychogeriatic Association. P. 27, 1991.
  12. Leuchter AF, Cook IA, Lufkin RB, Walter DO, Mena I, Miller BL: Quantitative EEG, PET, and SPECT in brain disease. 1992 CME Syllabus & Proceedings Summary, American Psychiatric Association, 145thAnnual Meeting. P.103,Washington, D.C., May 2-7, 1992.
  13. Cook IA, Leuchter, AF, Newton TN. “Quantitative EEG and diagnosis of dementia.” 1992 CME Syllabus & Proceedings Summary, American Psychiatric Association, 145th Annual Meeting., Washington, D.C., May 2-7, 1992.
  14. Newton TF, Leuchter AF, Cook IA, Walter DO: Quantitative EEG coherence and subcortical dysfunction in AIDS. 1992 CME Syllabus & Proceedings Summary, American Psychiatric Association, 145th Annual Meeting. P.258, 1992.
  15. Jacobson SA, Leuchter AF: Serial EEG and quantitative EEG in delirium. 1992 CME Syllabus & Proceedings Summary, American Psychiatric Association, 145th Annual Meeting. P.259, 1992.
  16. Newton TF, Leuchter AF, Cook I, Walter D, Dunkin J, Lachenbruch P. “Dementia as a syndrome of cortical disconnection.” American Electroencephalographic Society 1992 Annual Meeting and Courses Program. p. 96, 1992.
  17. Leuchter AF, Cook IA, Mena I, Dunkin J, Newton TF, Lufkin RB, Mackey, Walter DO, Cummings JL, Lachenbruch P: A new method for assessment of cerebral perfusion and metabolism. American Electroencephalographic Society 1992 Annual Meeting and Courses Program. P.96, 1992.
  18. Newton TF, Leuchter AF, Cook IA, Walter DO, Dunkin J, Lachenbruch P: Dementia as syndrome of cortical disconnection. American Electroencephalographic Society 1992 Annual Meeting and Courses Program. 1992.
  19. Cook IA, Leuchter AF, O’Hara R, Newton TF, Walter DO: Assessment of cognitive processes using EEG. American Electroencephalographic Society 1992 Annual Meeting and Courses Program. 1992.
  20. Dunkin JJ, Leuchter AF, Cook IA, Newton TF, Rosenberg-Thompson S: Longitudinal changes in EEG power and coherence in normal and abnormal aging: relationship to mental status changes. Journal of Clinical and Experimental Neuropsychology. Vol. 15, p.31, 1993.
  21. Dunkin JJ, Leuchter AF, Cook IA, Newton TF, Rosenberg-Thompson S: “Longitudinal changes in EEG power and coherence in normal and abnormal aging: relationship to mental status changes.” Journal of Clinical and Experimental Neuropsychology. 11: 31. 1993.
  22. Leuchter A, Newton T, Cook I, Dunkin J, Holschneider D, Lufkin R, Mena I: Neuroimaging findings in normal and pathologic aging. Abstract presented at the Sixth Congress of the International Psychogeriatric Association. Berlin, Germany, September 5-10, 1993.
  23. Leuchter AF, Newton TF, Cook IA. “QEEG: a cost effective view of the brain.” 1993 CME Syllabus & Proceedings Summary, American Psychiatric Association, 146th Annual Meeting. San Francisco, CA, May 1993.
  24. Leuchter A, Newton T, Cook I, Dunkin J, Holschneider D, Lufkin R, Mena I: “Neuroimaging findings in normal and pathologic aging.” Abstract presented at the Sixth Congress of the International Psychogeriatric Association. Berlin, Germany, September 5-10, 1993.
  25. Leuchter A, Cook I: Quantitative electroencephalography as a measure of synaptic plasticity in dementia. First International Conference on Synaptic Plasticity. Freiburg, Germany, October 1994.
  26. Cook IA. “Regional brain activity in the study of human consciousness.” Invited paper presented at the International Institute of Biophysics, Neuss, Germany. May 19-21, 1995.
  27. Newton TF, Leuchter AF, Cook IA, Beckson M, Uijtdehaage S, Simon SL, Goldman M, Londholm J, Santiago I, Ling W: Acute cocaine administration reverses EEG signs of cocaine withdrawal. Problems of Drug Dependence 1995: Proceedings of the 57th Annual Scientific Meeting. The College on Problems of Drug Dependence, Inc. National Institute on Drug Abuse Research Monograph Series, No. 162, p.142, 1995.
  28. Leuchter AF, Cook IA, Uijtdehaage SH, Lufkin RB, Dunkin JJ, Abrams M, Rosenberg-Thompson S, Simon SL, O’Hara R. “Brain imaging in the depressed elderly.” Presented at the symposium Late Life Depression: Recent Advances in Assessment and Treatment. American Psychiatric Association. Boston MA. 1995.
  29. Badjatia N, Cook IA, Markee T, Leuchter AF, Uijtdehaage S. “Correlation of deep white matter disease on MRI with neuropsychological testing in the elderly.” Poster presented at the joint American Geriatrics Society and American Federation for Aging Research Annual Meeting. 1996.
  30. Leuchter AF, Uijtdehaage SH, O’Hara R, Cook IA, Mandelkern M, Newton TF, Ling W: Validation of a non-invasive method for monitoring drug effects in clinical trials. Abstracts of the College on Problems of Drug Dependence 58th Annual Scientific Meeting, June 22-27, 1996, p. 80, 1996.
  31. Leuchter AF, Cook IA, Uijtdehaage SH, Lufkin RB, Abrams M, Rosenberg-Thompson S: Brain function and the outcomes of treatment for depression. Abstracts of the X World congress of Psychiatry, Madrid, August 23-28, 1996, Volume 1, p.80, 1996.
  32. Holschneider DP, Leuchter AF, Walton NY, Scremin OU, Treiman DM: NGF infusions in rats with Nucleus basalis lesions: quantitative electroencephalographic and cholinergic correlates of recovering brain function. Abstract presented at annual meeting of the American Geriatric Society, Chicago, IL, May 4, 1996.
  33. Leuchter AF, Cook IA, Uijtdehaage SH, O’Hara R, Mandelkern M: Non-invasive monitoring of brain function. Abstract presented at the American Psychiatric Association Annual Meeting. San Diego, California, May 17-22, 1997.
  34. Cook IA, Leuchter AF, Uijtdehaage SH, Osato S, Holschneider DH, Abrams M, Rosenberg-Thompson S. “Altered Cerebral Energy Utilization in Late Life Depression. “ Poster presented at the NCDEU Annual Meeting. Boca Raton, Florida, May 29-30, 1997.
  35. Leuchter AF, Cook IA, Uijtdehaage SH, Dunkin J, Anderson-Hanley C, Abrams M, Rosenberg-Thompson S: Neurophysiologic prediction of antidepressant treatment response. Poster presented at the NCDEU Annual Meeting. Boca Raton, Florida, May 29-30, 1997.
  36. Leuchter AF, Uijtdehaage SHJ, Simon SL, Rawon R, Ling W: QEEG cordance detects changes in brain function among methamphetamine abusers. Abstract presented at the fifty-ninth annual CPDD meeting in Nashville, TN, June 14-19, 1997.
  37. Dunkin JJ, Cook IA, Leuchter AF, Kasl-Godley JE, Abrams M, Betz B, Anderson- Hanley C: Executive dysfunction predicts non-response to fluoxetine in major depression. Journal of the International Neurological Society 4:5, 1997.
  38. Holschneider DP, Leuchter AF, Abrams M, Rosenberg-Thompson S: Attenuation of brain high frequency response after thiopental in early stages of Alzheimer’s dementia. Abstract presented at annual meeting of the American Association for Geriatric Psychiatry, San Diego, CA March 10, 1988.
  39. Leuchter AF, Cook IA, Rosenberg-Thompson S, Abrams M, Uijtdehaage SHJ, Anderson-Hanley C, Dunkin J. Differential therapeutic responses in depression. Abstract presented at a symposium, “Predicting Outcomes of Antidepressant Treatment “ at the American Psychiatric Association Annual Meeting, Toronto, Canada, May 30-June 4, 1998.
  40. Cook IA, Leuchter AF, Uijtdehaage SHJ, Abrams M, Anderson-Hanley C, Rosenberg- Thompson S, Dunkin J: Neurophysiologic predictors of treatment response. Abstract presented at a symposium, “Predicting Outcomes of Antidepressant Treatment” at the American Psychiatric Association Annual Meeting, Toronto, Canada, May 30-June 4, 1998.
  41. Leuchter AF, Cook IA, Witte E, Abrams M, Anderson-Hanley C, Rosenberg-Thompson S, Uijtdehaage SHJ, Dunkin J. Predictors of differential response to antidepressant medication. Abstract presented at the 1998 Annual Meeting of the American Psychiatric Electrophysiology Association, Toronto, Canada, May 30-31, 1998.
  42. Leuchter AF, Bartzokis G, Venneman S, Beckson M, Wilkins J, Schaeffer M, Ling W: Neurophysiologic predictors of successful completion of a cocaine treatment trial. Poster presented at the sixtieth annual CPDD meeting in Scottsdale, Arizona, June 13-18, 1998.
  43. Leuchter AF, Bartzokis G, Venneman S, Beckson M, Wilkins J, Schaeffer M, Rawson R, Ling W: Neurophysiologic predictors of subject retention in a cocaine treatment trial. Poster presented at the NCDEU Annual meeting. Boca Raton, Florida, June 10-13, 1998.
  44. Dunkin JJ, Cook IA, Leuchter AF, Kasl-Godley JE, Abrams M, Betz B, Anderson-Hanley C. Executive dysfunction predicts nonresponse to fluoxetine in major depression. Journal of the International Neuropsychological Society. 4:5. 1998.
  45. Anderson-Hanley C, Dunkin JJ, Cook IA, Leuchter AF, Abrams M, Kasl-Godley JE. Frontal brain activation and asymmetry abnormalities in depressed patients with executive function compromise. Journal of the International Neuropsychological Society. 4:5. 1998
  46. Betz B, Dunkin JJ, Leuchter AF, Witte E, Cook IA. Utility of the modified Wisconsin Card Sort Test in detecting cognitive changes associated with white matter lesions. Journal of the International Neuropsychological Society. 4:65. 1998.
  47. Witte EA, Leuchter AF, Cook IA, Dunkin JJ, Broumandi D, Abrams M, Rosenberg-Thompson S, Lightner A, Thomas S, Babaie A, Badjatia N. Neurophysiology of normal aging and depression. Poster presented at the 1998 Annual Meeting, Society for Neuroscience, Los Angeles CA 1998.
  48. Witte EA, Leuchter AF, Cook IA, Dunkin JJ, Broumandi D, Abrams M, Rosenberg-Thompson S, Lightner A, Thomas S, Babaie A, Badjatia N. Neurophysiology of normal aging and depression. Poster presented at the Third Annual UCLA Research Conference on Aging. Los Angeles. 1998.
  49. Dunkin JJ, Cook IA, Leuchter AF, Kasl-Godley J, Abrams M. The longitudinal course of cognitive dysfunction in major depression. Journal of the International Neuropsychological Society. 5: 132. 1999.
  50. Dunkin JJ, Leuchter AF, Cook IA, Broadway L, David S, Abrams M, Kasl-Godley J. Effects of multiple episodes of major depression on cognitive performance. Poster presented at the 28th Annual Meeting of the International Neuropsychological Society, Denver, Colorado, February 2000.
  51. Cook IA, Stubbeman WF, Witte E, Leuchter AF: Neurophysiologic Measures and Treatment Response in Depression. Presented at the West Coast College of Biological Psychiatry Annual Meeting, San Diego, CA, April 14, 2000.
  52. Cook IA, Leuchter AF, Witte E, Stubbeman WF: Prefrontal changes predict speed and completeness of antidepressant response: Poster presented at the New Research session, American Psychiatric Association Annual Meeting, Chicago, IL, May 15 – 17, 2000.
  53. Stubbeman WF, Leuchter AF, Cook IA, Shurman B, Gunay I, Gonzalez S: Neurophysiologic prediction of ECT response in depression. Poster presented at the New Research session, American Psychiatric Association Annual Meeting, Chicago, Illinois, May 15 – 17, 2000.
  54. Leuchter AF, Cook IA, Witte EA, Abrams M: Brain functional and structural differences between medication and placebo responders. Poster presented at the NCDEU Annual meeting. Boca Raton, Florida, May 29-31, 2000.
  55. Cook IA, Leuchter AF, Witte E, Stubbeman WF: Prefrontal changes predict speed and completeness of antidepressant response. Poster presented at the NCDEU Annual Meeting. Boca Raton, Florida, May 29 – June 1, 2000.
  56. Stubbeman WF, Leuchter AF, Cook IA, Shurman B, Gunay I, Gonzalez S: Neurophysiologic prediction of ECT response in depression. Poster presented at the NCDEU Annual Meeting. Boca Raton, Florida, May 29 – June 1, 2000.
  57. David S, Morgan M, Cook IA, Babaie A, Lightner A, Thomas S, Broumandi D, Mody R, Aroya S, Zheng Z, Leuchter AF: Regional changes in cerebral tissue volume in normal aging. Poster presented at the UCLA Research Conference on Aging. Los Angeles, California, June 21, 2000.
  58. David S, Morgan M, Cook IA, Babaie A, Lightner A, Thomas S, Broumandi D, Mody R, Aroya S, Zheng Z, Leuchter AF: Regional changes in cerebral tissue volume in normal aging Poster presented at the 12th Annual UCLA Brain Research Institute Neuroscience Poster Session, Los Angeles, California, December 5, 2000.
  59. Dunkin J, Leuchter A, Cook I, Broadway L, David S, Abram M, Kasl-Godley J. Effects of multiple episodes of major depression on cognitive performance. Journal of the International Neuropsychological Society. 6: 214. 2000.
  60. Leuchter AF, Cook IA, Witte EA, Abrams M: Brain functional and structural differences between medication and placebo responders. Poster presented at the 11th Biennial Congress on Pharmaco-EEG, International Pharmaco-EEG Society, Vienna, Austria, September 1-3, 2000.
  61. Cook IA, Leuchter AF, Witte E, Stubbeman WF. Prefrontal changes predict speed and completeness of antidepressant response. Poster presented at the 11th Biennial Congress on Pharmaco-EEG, International Pharmaco-EEG Society, Vienna, Austria, September 1-3, 2000.
  62. Krell HV, Cook IA, Abrams M, Hanson K, Tolbert T, Leuchter AF. Reboxetine yields symptomatic and functional improvement in unipolar depression. Poster presented at the NCDEU Annual Meeting. Phoenix, Arizona, May 28-31,2001.
  63. Cook IA, Leuchter AF, Morgan M, David S, Dunkin J, Lufkin R. Subclinical structural brian disease: longitudinal progression in normal aging. Poster presented at the NCDEU Annual Meeting. Phoenix, Arizona, May 28-31,2001.
  64. Leuchter AF, Cook IA, David S, Dunkin JJ, Lufkin R. Longitudinal subclinical structural brain disease in normal aging. Poster presented at the American Psychiatric Association Annual Meeting, New Orleans, LA, May 5-10, 2001.
  65. Leuchter AF, Cook IA, Greenwald S, Morgan M, Hanson K, Siegman B. Bispectral Index (BIS) Correlates With Dementia Severity in AD and VAD. Poster presented at the American Psychiatric Association Annual Meeting, Philadelphia, PA, May 19-23, 2002.
  66. Cook IA, Leuchter AF, Greenwald SD, Morgan ML, Hanson K, Siegman, B. Single-channel EEG bispectrum predicts antidepressant treatment response. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, May 28 – 31, 2002.
  67. Cook IA, Leuchter AF, Greenwald SD, Morgan ML, Hanson K, Siegman, B. EEG bispectrum differentiates Alzheimer’s from vascular dementia. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, May 28 – 31, 2002.
  68. Morgan ML, Cook IA, Greenwald SD, Hanson K, Siegman B, Leuchter AF. EEG Bispectral Index correlates with dementia severity in AD and VAD. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, May 28 – 31, 2002.
  69. Cook IA, Leuchter AF, Greenwald SD, Morgan ML, Hanson K, Siegman B, Johnstone J. EEG bispectrum shows characteristic changes with increasing impairment in Alzheimer’s and vascular dementia. Poster presented at the 8th International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden. July 20-25, 2002.
  70. Leuchter AF, Cook IA, Greenwald SD, Morgan ML, Hanson K, Siegman B, Johnstone J. The EEG Bispectral Index (BIS™) correlates with severity of dementia in patients with Alzheimer’s disease or vascular dementia. Poster presented at the 8th International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden. July 20-25, 2002.
  71. Morgan ML, VanBatenburg C, Cook IA, Leuchter AF, Rapkin A, Siegman B, Mickes L. Serum estrogen levels in perimenopause, memory and mood. Poster presented at the American Psychiatric Association Annual Meeting. San Francisco, CA, May 17-22, 2003.
  72. Leuchter AF, DeBrota DJ, Cook IA, Morgan ML, Abrams MJ, Siegman B, Cohen J, Mickes L, Krell H, Potter WZ. Physiologic assessment of antidepressant drug effects in normal and depressed subjects. Poster presented at the American Psychiatric Association Annual Meeting. San Francisco, CA, May 17-22, 2003.
  73. Krell H, Leuchter AF, Cook IA, Morgan ML, Abrams MJ. Patient expectation as a predictor of outcome in antidepressant treatment. Poster presented at the American Psychiatric Association Annual Meeting. San Francisco, CA, May 17-22, 2003.
  74. Hunter AM, Leuchter AF, Morgan ML, Cook IA, DeBrota D, Potter WZ. Brain function correlates of side effects in normal subjects randomized to venlafaxine versus placebo. Poster presented at the American Psychiatric Association Annual Meeting. San Francisco, CA, May 17-22, 2003.
  75. Cook IA, Leuchter AF, Morgan ML, Abrams MJ. Changes in QEEG cordance and treatment resistant depression. Poster presented at the American Psychiatric Association Annual Meeting. San Francisco, CA, May 17-22, 2003.
  76. Cook IA, Leuchter AF, Greenwald SD, Morgan ML, Abrams MJ, Siegman B. QEEG cordance changes predict treatment response to reboxetine in major depression. Poster presented at the American Psychiatric Association Annual Meeting. San Francisco, CA, May 17-22, 2003.
  77. Morgan ML, Van Battenburg C, Cook IA, Leuchter AF, Rapkin A, Siegman B, Mickes L. Estrogen augmentation in perimenopausal depression. Poster presented at the American Psychiatric Association Annual Meeting, San Francisco, CA, May 17-22, 2003.
  78. Morgan ML, Van Batenburg C, Cook IA, Leuchter AF, Rapkin A, Siegman B, Mickes L. Serum estrogen levels in perimenopause, memory and mood. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, May 27-30, 2003.
  79. Leuchter AF, DeBrota DJ, Cook IA, Morgan ML, Abrams MJ, Siegman B, Cohen J, Mickes L, Krell H, Potter WZ. Physiologic assessment of antidepressant drug effects in normal and depressed subjects. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, May
    27-30, 2003.
  80. Krell H, Leuchter AF, Cook IA, Morgan ML, Abrams MJ. Patient expectation as a predictor of outcome in antidepressant treatment. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, May 27-30, 2003.
  81. Cook IA Leuchter AF, Greenwald SD, Morgan ML, Abram MJ, Siegman B. Changes in QEEG cordance predict response in treatment resistant depression and in reboxetine monotherapy. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, May 27-30, 2003.
  82. Wagner-Steh K, Dunkin JJ, Leuchter AF, Cook IA, David S, Kasl-Godley J, Abrams M. Interaction of age and depression on cognitive functioning. Poster presented at the UCLA Aging Conference. Los Angeles, CA, June 25, 2003.
  83. Leuchter AF. Dual-action antidepressants: the new frontier for treatment for co morbid depression. Psychiatry in Clinical Practice 4:300 2003.
  84. Leuchter AF, Cook IA, Greenwald SD, Kofol T. Prefrontal EEG Cordance Correlates with Anterior Cingulate Perfusion. Poster presented at the New Research session, American Psychiatric Association Annual Meeting. New York, New York, May 1-6, 2004.
  85. Leuchter AF, Morgan ML, Cook IA, Greenwald SD, Devlin P. Prospective evaluation of a model for identification of placebo responders prior to randomization in treatment trials for MDD. Poster presented at the American Psychiatric Association Annual Meeting, New York, NY, May 1-6, 2004.
  86. Cook IA, Leuchter AF, Morgan ML, Mickes L, Siegman B. Drug Sensitivity and Periventricular Hyperintensities in the Aging Brain. Poster presented at the American Psychiatric Association Annual Meeting. New York, New York, May 1-6, 2004.
  87. Leuchter AF, Morgan ML, Cook IA, Greenwald SD, Devlin P. Prospective Evaluation of a Model for Identification of Placebo Responders Prior to Randomization in Treatment Trials for MDD. Poster presented at the NCDEU Annual Meeting. Phoenix, Arizona, June 1-4, 2004.
  88. Cook IA, Leuchter AF, Morgan ML, Abrams MJ, Mickes L, Siegman B. Drug Sensitivity in the Aging Brain and Periventricular Hyperintensities. Poster presented at NCDEU Annual Meeting. Phoenix, Arizona, June 1-4, 2004.
  89. Hunter AM, Leuchter AF, Cook IA, Morgan ML. Changes in brain function during placebo lead-in and treatment outcome in clinical trials for major depression. Poster presented at the NCDEU Annual Meeting. Phoenix, Arizona, June 1-4, 2004
  90. Leuchter AF, Cook IA, Hunter A, Morgan ML, McGrouther C, Abrams M. Functional changes in the brain associated with clinical response to duloxetine. Poster presented at the XXIV CINP 2004 Congress. Paris, France, June 20-24, 2004.
  91. Leuchter AF. Are serotonin and norepinephrine the key to complete symptom resolution? Journal of Psychosomatic Research 56: 581-673, 2004.
  92. Leuchter AF, Cook IA, Hunter AM, Morgan ML, McGrouther C, Abrams M. Functional changes in the brain associated with remission in major depressive disorder. Poster presented at the SOBP Annual Meeting. Atlanta, Georgia, May 19-21, 2005.
  1. Leuchter AF, Kofol T, Greenwald SD, Devlin P, Cook IA. Source localization of anterior cingulate activity: comparison of 4 versus 24 channel EEG techniques. Poster presented at the APA Annual Meeting. Atlanta, Georgia, May 21-26, 2005.
  2. Cook IA, Shapiro D, Leuchter AF, Abrams M, Ottaviani C. Yoga augmentation and remission in partial responders to antidepressant medications. Poster presented at the APA Annual Meeting, Atlanta, Georgia, May 21-26, 2005.
  3. Morgan ML, Cook IA, Rapkin AJ, Leuchter AF. Brain function and estrogen augmentation in perimenopausal depression. Poster presented at the NCDEU Annual Meeting, Boca Raton, Florida, June 6-10, 2005.
  4. Cook IA, Shapiro D, Leuchter AF, Abrams M, Ottaviani C. Yoga augmentation and remission in partial responders to antidepressant medications. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, June 6-9, 2005.
  5. Cook IA, Hunter AM, Abrams M, Siegman B, Leuchter AF. Midline and right frontal brain function and remission in major depression. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, June 12-15, 2006.
  6. Morgan ML, Rapkin A, Rasgon NL, Cook IA, Leuchter AF. Neuroactive steroids, estrogen, and sertraline in menopausal depression. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, June 12-15, 2006.
  7. Leuchter AF, Cook IA, Siegman B, Kofol T, Greenwald SD, Devlin P. EEG antidepressant response index correlates with anterior cingulate perfusion in normal subjects. Poster presented at the EEG and Clinical Neuroscience Society (ECNS) Annual Meeting. Boston, MA, September 13-17, 2006.
  8. Cook IA, Schairer D, Leuchter AF. Altered circuit connectivity in depression is detected with current source coherence. Presented at the West Coast Collage of Biological Psychiatry Annual Meeting, Tucson, AZ, April 20-21, 2007.
  9. Korb A, Cook IA, Schairer D, Leuchter AF. Sex differences in regional brain current density in MDD. Presented at the West Coast Collage of Biological Psychiatry Annual Meeting, Tucson, AZ, April 20-21, 2007.
  10. Leuchter AF, Cook IA, Marangell LB, Gilmer WS, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Iosifescu D, Fava M, Manberg P. Biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD): Predictors of clinical treatment response. Poster presented at the Society of Biological Psychiatry Annual Meeting. San Diego, CA. May 17, 2007.
  11. Leuchter AF, Cook IA, Gilmer WS, Greenwald SD, Howland RH, Trivedi MH. Can EEG-guided antidepressant selection improve response rates? Insights from the BRITE-MD Trial. Poster presented at the New Research session, American Psychiatric Association Annual Meeting. San Diego, CA. May 21, 2007.
  12. Leuchter AF, Marangell LB, Burgoyne KS, Sigl J, Jain R, Zisook S, Fava M. Biomarkers for rapid identification of treatment effectiveness in major depresssion (BRITE-MD): A Prospective Evaluation of an EEG Biomarker. Poster presented at the New Research session, American Psychiatric Association Annual Meeting. San Diego, CA. May 21, 2007.
  13. Cook IA, Schairer D, Leuchter AF. Current source coherence detects neural circuit differences in major depression. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, June 11-14, 2007.
  14. Leuchter AF, Cook IA, Gilmer W, Sigl J, Howland R, Iosifescu D, Trivedi M. EEG-guided antidepressant selection may improve response rates: insights from the BRITE-MD trial. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, June 11-14, 2007.
  15. Englehardt N, Kobak K, Leuchter A, Williams J, Cook I, Leon A. Site vs. centralized raters in a clinical depression trial: impact on patient selection and placebo response. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, June 11-14, 2007.
  16. Leuchter AF, Cook IA, Marangell LB, Gilmer WS, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Iosifescu D, Greenwald S. Biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD): predictors of clinical response and remission to escitalopram treatment. Poster presented at the American College of Neuropsychopharmacology 46th Annual Meeting. Boca Raton, FL, December 9-13, 2007.
  17. Leuchter AF, Marangell LB, Burgoyne KS, Sigl JC, Jain R, Zisook S, McCracken JT, Iosifescu DV. Biomarkers for rapid identification of treatment effectiveness (BRITE): testing symptoms and biomarkers as predictors of response and remission in MDD. Poster presented at the 2008 American Psychiatric Association Annual Meeting. Washington, D. C., May 5 2008.
  18. Cook IA, Leuchter AF, Gilmer WS, Greenwald SD, Howland RH, Trivedi MH. ATR-guided antidepressant selection may improve response and remission rates: insights from the BRITE-MD trial. Poster presented at the 2008 American Psychiatric Association Annual Meeting. Washington, D. C., May 5, 2008.
  19. Cook IA, Leuchter AF, Marangell LB, Gilmer WS, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Iosifenscu DV, Greenwald S. QEEG biomarker status and time to remission during treatment in MDD. Poster presented at the NCDEU Annual Meeting. Phoenix AZ, May 27-30, 2008.
  20. Leuchter AF, Cook IA, Marangell LB, Gilmer WS, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Iosifescu DV, McCracken JT, Fava M, Greenwals S. Biomarkers for rapid identification of treatment effectiveness in major depression: predictors of response and remission to antidepressant treatment. Poster presented at the NCDEU Annual Meeting. Phoenix AZ, May 27-30, 2008.
  21. Farahbod H, Cook IA, Schairer D, Korb A, Leuchter AF. Modulatory effects of comorbid anxiety on neuronal circuitry in depression using current source coherence. Poster presented at the Society for Neuroscience Annual Meeting, Washington DC, November 15-19, 2008.
  22. Leuchter AF, Trivedi MH, Fava M, Unutzer J, Laje G. Increasing the likelihood of achieving remission in depression. Symposium directed and presented at the American Psychiatric Association Annual Meeting. San Francisco, CA, May 18, 2009.
  23. Cook IA, Hunter AM, Farahbod H, Korb A, Leuchter AF. Detecting Cingulate Abnormalities in Major Depression with Prefrontal Midline EEG. Poster presented at the New Research session, American Psychiatric Association Annual Meeting. San Francisco, CA. May 19, 2009.
  24. Caudill M, Cook IA, Hunter AM, Leuchter AF. ATR as a Predictor of Response to Reboxetine. Poster presented at the New Research session, American Psychiatric Association Annual Meeting. New Orleans LA. May 24, 2010.
  25. Scanlon G, Leuchter AF, Cook IA, Hunter AM. Neurophysiologic correlates of headache pain in depressed subjects. Poster presented at the American Headache Society Annual Meeting. Los Angeles, CA, June 26, 2010.
  26. Cook IA, Gomez-Pinilla F, Hunter AM, Leuchter AF. Do Early Levels of Serum BDNF Predict Treatment Outcome in Major Depression? Poster presented at the NCDEU Annual Meeting. Boca Raton FL, June 13-16, 2011.
  27. Cook IA, DeGiorgio CM, Leuchter AF. Neuromodulation with Trigeminal Nerve Stimulation: Adjunctive Therapy in Comorbid Post-traumatic Stress Disorder and Major Depression. Poster session at US Psychiatric and Mental Health Congress. San Diego CA. November 8-11, 2012
  28. McGough J, Loo S, Leuchter AF, Cook I. Trigeminal Nerve Stimulation (TNS) for Attention-Deficit/Hyperactivity Disorder: A Pilot Feasibility Study. New Research Poster Session, American Psychiatric Association Annual Meeting, San Francisco CA. May 20, 2013.
  29. Cook IA, DeGiorgio CM, Leuchter AF. External Trigeminal Nerve Stimulation: Adjunctive Neuromodulation for Comorbid Posttraumatic Stress Disorder and Major Depression. Poster presented at the 53rd NCDEU Annual Meeting. Hollywood FL. May 28 – 30, 2013.
  30. Cook IA, Hunter AM, Caudill M, Leuchter AF. Personalized Response Indicators of SSRI Effectiveness in Major Depression (PRISE-MD): use of an EEG-based biomarker to guide treatment. Poster presented at the 53rd NCDEU Annual Meeting. Hollywood FL. May 28 – 30, 2013.
  31. Wedel PC, Gadient R, Targum SD, Leuchter AF, Hutchinson JH, Frisbie V, Troung C. The Selective Metabotropic Glutamate 2/3 Receptor Antagonist (BCI-632) in Development for Treatment Resistant Depression: Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Results. Poster presented at 53rdNCDEU Annual Meeting. Hollywood, FL. May 28-30, 2013.
  32. Leuchter AF, Hunter AM, Jain F, Tartter M, Cook IA. Targeting Changes in Brain Oscillatory Behavior as an Intermediate Phenotype in Depression. Abstract presented at the 69th Society of Biological Psychiatry Annual Symposium. New York, NY. May 8-10,2014.
  33. Leuchter AF, Phillips B, Cook IA, Feifel D, Goethe J, Husain M, Carpenter L, Thase M, Burke W, Sheline Y, Aaronson S, Iosifescu D, Gilmer W, Lisanby S, George M. Effectiveness of Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. Poster presented at the 69th Society of Biological Psychiatry Annual Symposium. New York, NY. May 8-10,2014.
  34. Cook IA, Leuchter AF, Jain FA, Caudill MM, Abrams M, DeGiorgio CM. Effect of Adjunctive Trigeminal Nerve Stimulation in Major Depressive Disorder in a Dose Ranging Trial. Poster 2.93 presented at the First International Brain Stimulation Conference. Singapore. March 2-4, 2015.
  35. Cook IA, Leuchter AF, Jain FA, Caudill MM, Abrams M, DeGiorgio CM. Adjunctive Trigeminal Nerve Stimulation in Major Depressive Disorder in a Dose Ranging Trial. Late Breaking Poster 1153, presented at the Society of Biological Psychiatry 70th Annual Meeting. Toronto, Canada. May 14-16, 2015.
  36. Cook IA, Leuchter AF, DeGiorgio CM. Non-invasive Neuromodulation with Trigeminal Nerve Stimulation in Major Depressive Disorder and Other CNS Disorders. Pharma Pipeline Poster I-4, ASCP/NCDEU Annual Meeting. Miami FL, June 22-25, 2015.